|
Champions Biotechnology, Inc. and Morphotek®, Inc. Announce Agreement for an Oncology Evaluation Using Biomerk Tumorgraft™ Platform 4/20/10
Champions Biotechnology Reports Fiscal 2010 Third Quarter Financial Results 3/17/10
Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results 12/15/09
Champions Biotechnology Enters into Licensing Agreement with Yale University and Southern Research Institute for the Repurposing of Bithionol for Oncology 11/18/09
Champions Biotechnology to Present Data at AACR-EORTC 2009 Regarding the Predictability of Biomerk Tumorgraft™ Platform to Guide Personalized Cancer Treatment and Accelerate Oncology Drug Development 11/12/09
Champions Biotechnology, Inc. Signs Exclusive Licensing Agreement with Ramot for TAR-1, a Novel Therapeutic for the Treatment of Cancer 10/27/09
Champions Biotechnology Expands Collaboration to Test Oncology Therapeutic in Biomerk Tumorgrafts™ 10/26/09
U.S. Patent Issues for Champions Biotechnology's Lead Oncology Drug 10/13/09
Champions Biotechnology Reports Fiscal 2010 First Quarter Financial Results 9/14/09
Champions Biotechnology and PinnacleCare Enter Into Personalized Oncology Collaboration Agreement 9/10/09
Champions Biotechnology to Present at Rodman & Renshaw's Eleventh Annual Healthcare Conference 9/9/09
Champions Biotechnology to Deploy its Technology to Guide Development of
Oncology Therapeutic for Global Biotech Leader 9/1/09
Champions Biotechnology Reports Fiscal 2009 Full-Year Financial Results 8/27/09
Champions Biotechnology Partners with Do-Coop Technologies to Advance its Novel Oncology Compound Into Biomerk Tumorgraft Testing 6/16/09
Champions Biotechnology, Inc. Launches PersonalizedCancerTreatment.com 6/1/09
Champions Biotechnology, Inc. Establishes UK Subsidiary and Retains General Manager to Expand its Personalized Oncology Business 4/8/09
Champions Biotechnology Reports Fiscal 2009 Third Quarter Financial Results 3/18/09
Champions Biotechnology Partners with Gradalis Inc. and Mary Crowley Cancer Research Center to Develop Personalized Vaccines for Cancer Patients 2/03/09
Champions Biotechnology, Inc. Appoints Three Key Executives to Management Team 1/20/09
Champions Biotechnology and Concordia Pharmaceuticals Establish Royalty Agreement for Novel Oncology Drug 1/12/09
Champions Biotechnology Partners to Establish Agreements for Preclinical Evaluation of Oncology Drugs 12/18/08
Champions Biotechnology Reports Fiscal 2009 Second Quarter Financial Results 12/16/08
Of Mice and Men: Award-Winning Oncologist Leads New Advancement in Personalized Medicine
Champions Biotechnology, Inc. Reports Fiscal 2009 First Quarter Financial Results 9/16/2008
Champions Biotechnology, Inc. Retains The Investor Relations Group 8/14/2008
Champions Biotechnology, Inc. Earnings Release 7/30/2008
Champions Biotechnology, Inc. Begins Preclinical Development of Its Lead Oncology Drug Candidate 6/17/2008
Champions Biotechnology, Inc. and ImClone Systems Establish Agreement for Preclinical Evaluation of Oncology Drugs 5/07/2008
Champions Biotechnology, Inc. and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs 5/06/2008
Champions Biotechnology, Inc. Completes $2,500,000 Private Financing at $1.75 per Share 4/23/2008
Champions Biotechnology, Inc. Appoints New Board Members and Forms Management Team 4/01/2008
Champions Biotechnology, Inc. Reports Two Cents per Share Earnings 3/06/2008
Dr. David Sidransky Appointed Chairman of Champions Biotechnology, Inc. 10/23/2007
Dr. David Sidransky Appointed Director of Champions Biotechnology, Inc. 8/14/2007
Dr. Manuel Hidalgo Appointed Director and Scientific Advisor of Champions Biotechnology, Inc. 6/11/2007
Champions Biotechnology, Inc. acquires Biomerk, Inc. 05/21/2007
Champions Biotechnology, Inc. acquires rights to cancer drug candidates. 02/14/2007
Champions Sports, Inc. changes name to Champions Biotechnology, Inc. 01/22/2007
|
